A two-year randomized trial in JAMA Cardiology found that 360 µg a day of vitamin K2 as MK-7 slowed coronary calcium buildup in people with symptomatic heart disease. Median CAC scores rose from 135 to 184 AU on MK-7 versus 145 to 214 AU on placebo. The effect appeared tied to noncalcified plaques becoming calcified, and no significant adverse effects were reported. But nobody yet knows whether this translates into fewer heart attacks, and one author disclosed grants from an MK-7 manufacturer. Here is what the study showed, what it didn't, and who should be careful, especially anyone taking warfarin.
This page is available in